Provides genetic tests for hereditary cancer risk assessment. Offers genetic testing for precision oncology to guide cancer treatment decisions. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 22% a year on average.
Sales run at $487M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
A loss of $0 against $487M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0003. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.